{"id":"W2083942034","doi":"10.1371/journal.pone.0054435","title":"The Potential Cost and Benefits of Raltegravir in Simplified Second-Line Therapy among HIV Infected Patients in Nigeria and South Africa","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Infection and Immunity","funders":"Australian Government; Gilead Sciences; Australian Research Council; University of New South Wales; Bristol-Myers Squibb","keywords":"Raltegravir; Medicine; Discontinuation; Lopinavir; Life expectancy; Quality-adjusted life year; Dolutegravir; Cost-effectiveness analysis; Cost effectiveness; Regimen; Ritonavir; Cost–benefit analysis; Orphan drug; Demography; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral load; Environmental health; Internal medicine; Population; Family medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001310741,0.0006609821,0.000688257,0.0004215711,0.0003923347,0.001148552,0.0007305713,0.0008899269,0.002511941],"category_scores_gemma":[0.003648626,0.0004921891,0.001226181,0.0003821772,0.0004227067,0.0007301196,0.0008772631,0.0007442878,0.0001009682],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003537195,"about_ca_system_score_gemma":0.002646337,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02323738,"about_ca_topic_score_gemma":0.01522372,"domain_scores_codex":[0.9995358,0.0002841466,0.00001825151,0.00004423382,0.00003468467,0.00008293857],"domain_scores_gemma":[0.9986311,0.001013374,0.000178244,0.00003338448,0.00006074803,0.00008317068],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","study_design_scores_codex":[0.001225588,0.0002055238,0.02838623,0.0001408301,0.0002161243,0.0005477915,0.00007139167,0.9603156,0.0004284146,0.001630084,0.000153008,0.006679443],"study_design_scores_gemma":[0.0006600274,0.001964539,0.01629383,0.0002455329,0.0004927821,0.000488775,0.0004098991,0.9749056,0.000897149,0.002708592,0.0008881331,0.00004515479],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937781,0.0006389497,0.002964564,0.0004257687,0.00001604202,0.0001164151,0.0002939582,0.00001370211,0.001752542],"genre_scores_gemma":[0.9986344,0.0001950372,0.0008040695,0.00003248296,0.0000020348,0.0000431726,0.00006051128,0.000001737675,0.0002265219],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02323738,"threshold_uncertainty_score":0.04620427,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02194987038773688,"score_gpt":0.2095478361881172,"score_spread":0.1875979658003804,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}